EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received U.S. Food and Drug ...

Surmodics, Inc. SRDX is well-poised for growth in the coming quarters, courtesy of its solid prospects in the thrombectomy business over the past few months. The optimism led by a solid second-quarter ...

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial ...

Analysis of the all-comers PROWL Registry demonstrated high procedural success and safety in a cohort reflecting the real-world complexity of patients with symptomatic limb ischemia, over 40% of whom ...

Surmodics, Inc. (NASDAQ:SRDX) shares are trading lower in the premarket session on Friday. The firm’s stock dipped following news that the U.S. Federal Trade Commission will challenge the proposed ...

PROWL Registry evaluates the Pounce™ Thrombectomy Platform for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. Updated safety and performance data from 160 ...

You certainly can’t accuse Bruce Barclay of standing still. Since SurModics Inc. (NASDAQ: SRDX) named Barclay CEO in 2005, Barclay has reorganized the drug company’s business units, purchased land, ...

Surmodics Inc said in a securities filing Monday that it was working with the Food and Drug Administration to clarify how the agency's Friday warning about paclitaxel-coated balloons and ...

A private equity firm’s bid to combine the two biggest makers of medical-device coatings would harm competition for life-saving technologies, the Federal Trade Commission said at the start of a trial ...

) announced after the market closed on Wednesday that it missed consensus Wall Street estimates. SurModics, Inc reported a 4th quarter net loss of $21.7 million, or $1.25 per share, compared to net ...